Examkin

Soru

Zorluk: OrtaGenetic and Molecular Mechanisms

A 45-year-old man presents with fatigue, early satiety, and massive splenomegaly. Laboratory studies show a leukocyte count of 85,000/μL85,000/\mu\text{L} with a full spectrum of granulocytic differentiation. Cytogenetic analysis confirms a t(9;22) chromosomal translocation, and the patient is started on a targeted oral pharmacologic agent. Arrange the following molecular events in the correct chronological order, beginning with the underlying genetic aberration and concluding with the cellular response to the therapeutic intervention.

  1. 1Reciprocal translocation between chromosomes 9 and 22 forming a fusion oncogene
  2. 2Translation of a constitutively active, non-receptor tyrosine kinase
  3. 3Competitive binding of the targeted inhibitor to the ATP-binding site of the kinase
  4. 4Prevention of downstream substrate phosphorylation and signaling cascade activation
  5. 5Suppression of unregulated cellular proliferation and induction of leukemic cell apoptosis

Cevap

The correct chronological sequence is: 1) Reciprocal translocation forming a fusion oncogene, 2) Translation of a constitutively active tyrosine kinase, 3) Competitive binding of the inhibitor to the ATP-binding site, 4) Prevention of downstream substrate phosphorylation, and 5) Suppression of cellular proliferation and induction of apoptosis.
The pathogenesis and targeted treatment of Chronic Myeloid Leukemia (CML) follow a specific sequential molecular cascade. The initiating event is the t(9;22) translocation, which creates the BCR-ABL1 fusion gene. This gene is translated into a constitutively active tyrosine kinase that drives unregulated cellular proliferation. Targeted therapies, such as imatinib, work by competitively binding to the ATP-binding site of this mutant kinase. This binding prevents the phosphorylation of downstream substrates, thereby disrupting the oncogenic signaling cascade. The deprivation of these essential survival and proliferation signals ultimately forces the leukemic cells to undergo apoptosis.

Adım Adım Çözüm

1
Identify the underlying genetic aberration
The t(9;22) translocation creates the BCR-ABL1 fusion gene.
This is the initiating chromosomal event in Chronic Myeloid Leukemia (CML).
2
Determine the molecular consequence of the gene fusion
The fusion gene is translated into a constitutively active tyrosine kinase.
The BCR-ABL1 protein structurally drives unregulated signaling in the cytoplasm.
3
Identify the mechanism of action of the targeted therapy
The pharmacologic agent competitively binds to the ATP-binding pocket of this mutant kinase.
Targeted therapy (e.g., imatinib) directly and physically inhibits the mutant protein's functional site.
4
Determine the immediate biochemical result of drug binding
Downstream substrate phosphorylation and signaling cascades are prevented.
Without ATP, the kinase cannot activate its downstream downstream effectors.
5
Identify the final cellular outcome
Unregulated cellular proliferation is suppressed, leading to leukemic cell apoptosis.
Deprivation of survival signals causes the malignant cells to undergo programmed cell death.

Anahtar Kavram

Molecular pathogenesis and the exact mechanism of targeted tyrosine kinase inhibitors in Chronic Myeloid Leukemia.
Bu soruyu puanla

Konular

Genetic and Molecular Mechanisms

Bu konudan daha fazla soru